Crystal Structure and Mechanism of Human Carboxypeptidase O: Insights Into Its Specific Activity for Acidic Residues
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
1 Evidence for Gliadin Antibodies As Causative Agents in Schizophrenia
1 Evidence for gliadin antibodies as causative agents in schizophrenia. C.J.Carter PolygenicPathways, 20 Upper Maze Hill, Saint-Leonard’s on Sea, East Sussex, TN37 0LG [email protected] Tel: 0044 (0)1424 422201 I have no fax Abstract Antibodies to gliadin, a component of gluten, have frequently been reported in schizophrenia patients, and in some cases remission has been noted following the instigation of a gluten free diet. Gliadin is a highly immunogenic protein, and B cell epitopes along its entire immunogenic length are homologous to the products of numerous proteins relevant to schizophrenia (p = 0.012 to 3e-25). These include members of the DISC1 interactome, of glutamate, dopamine and neuregulin signalling networks, and of pathways involved in plasticity, dendritic growth or myelination. Antibodies to gliadin are likely to cross react with these key proteins, as has already been observed with synapsin 1 and calreticulin. Gliadin may thus be a causative agent in schizophrenia, under certain genetic and immunological conditions, producing its effects via antibody mediated knockdown of multiple proteins relevant to the disease process. Because of such homology, an autoimmune response may be sustained by the human antigens that resemble gliadin itself, a scenario supported by many reports of immune activation both in the brain and in lymphocytes in schizophrenia. Gluten free diets and removal of such antibodies may be of therapeutic benefit in certain cases of schizophrenia. 2 Introduction A number of studies from China, Norway, and the USA have reported the presence of gliadin antibodies in schizophrenia 1-5. Gliadin is a component of gluten, intolerance to which is implicated in coeliac disease 6. -
THESIS Entitled Studies on Fraction 1 Protein of Beta Vulgaris Submitted for the Degree of DOCTOR of PHILOSOPHY by Kenneth Edwar
THESIS entitled Studies on Fraction 1 Protein of Beta vulgaris Submitted for the degree of DOCTOR OF PHILOSOPHY by Kenneth Edward Moon 1 970 TABLE OF CONTENTS Acknowledgements i Abbreviations i Summary ii Chapter 1 Introduction 1.1 Carbon Dioxide Fixation in the Calvin • 1 Cycle 1.2 Some Properties of RuDPcase and Similarity 2 to Fraction 1 Protein 1.3 Cellular Location of Fraction 1 Protein 3 1.4 The Mechanism of Action of RuDPcase 4 1.5 Structure of Fraction 1 Protein from 13 Higher Plants 1.6 Relationship of Structure to Enzymic 14 Activity and Role of Sulphydryl Groups 1.7 Studies on RuDPcase from Sources other 17 than the Higher Plants 1.8 Comparison of Some Kinetic and Physical 21 Constants of RuDPcase from Different Sources 1.9 Aim of This Research Project 23 Chapter 2 Methods and Materials 2.1 Plant Material 24 2.2 Preparation of Chloroplasts and Isolation 24 of Fraction 1 Protein 2.3 Concentrating Protein Solutions 26 2.4 Preparation of Reduced and Carboxy- 27 methylated Fraction 1 Protein 2.5 Preparation of Maleyl-carboxymethyl 28 Fraction 1 Protein 2.6 Removal of Maleyl Groups 29 2.7 Gel Electrophoresis 30 2.7 (i) Polyacrylamide Disk Electrophoresis 30 (ii) Polyacrylamide Electrophoresis in 31 the presence of SDS (iii) Slab Acrylamide Gel Electrophoresis 32 (iv) Isoelectric Focusing 33 2.8 Ribulose-1,5-diphosphate Carboxylase 3^ Assay 2.9 Preparation of the S-Sulphenylsulphanate 34 Derivative of Fraction 1 Protein 2.10 Edman Degradations 35 2.11 Hydrazinolysis 35 2.12 Isolation of Blocked N-Terminal Peptides 36 2.13 Tryptic -
Molecular Markers of Serine Protease Evolution
The EMBO Journal Vol. 20 No. 12 pp. 3036±3045, 2001 Molecular markers of serine protease evolution Maxwell M.Krem and Enrico Di Cera1 ment and specialization of the catalytic architecture should correspond to signi®cant evolutionary transitions in the Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Box 8231, St Louis, history of protease clans. Evolutionary markers encoun- MO 63110-1093, USA tered in the sequences contributing to the catalytic apparatus would thus give an account of the history of 1Corresponding author e-mail: [email protected] an enzyme family or clan and provide for comparative analysis with other families and clans. Therefore, the use The evolutionary history of serine proteases can be of sequence markers associated with active site structure accounted for by highly conserved amino acids that generates a model for protease evolution with broad form crucial structural and chemical elements of applicability and potential for extension to other classes of the catalytic apparatus. These residues display non- enzymes. random dichotomies in either amino acid choice or The ®rst report of a sequence marker associated with serine codon usage and serve as discrete markers for active site chemistry was the observation that both AGY tracking changes in the active site environment and and TCN codons were used to encode active site serines in supporting structures. These markers categorize a variety of enzyme families (Brenner, 1988). Since serine proteases of the chymotrypsin-like, subtilisin- AGY®TCN interconversion is an uncommon event, it like and a/b-hydrolase fold clans according to phylo- was reasoned that enzymes within the same family genetic lineages, and indicate the relative ages and utilizing different active site codons belonged to different order of appearance of those lineages. -
Differential Proteomic Analysis of the Pancreas of Diabetic Db/Db Mice Reveals the Proteins Involved in the Development of Complications of Diabetes Mellitus
Int. J. Mol. Sci. 2014, 15, 9579-9593; doi:10.3390/ijms15069579 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Article Differential Proteomic Analysis of the Pancreas of Diabetic db/db Mice Reveals the Proteins Involved in the Development of Complications of Diabetes Mellitus Victoriano Pérez-Vázquez 1,*, Juan M. Guzmán-Flores 1, Daniela Mares-Álvarez 1, Magdalena Hernández-Ortiz 2, Maciste H. Macías-Cervantes 1, Joel Ramírez-Emiliano 1 and Sergio Encarnación-Guevara 2 1 Depto. de Ciencias Médicas, División de Ciencias de la Salud, Campus León, Universidad de Guanajuato, León, Guanajuato 37320, Mexico; E-Mails: [email protected] (J.M.G.-F.); [email protected] (D.M.-A.); [email protected] (M.H.M.-C.); [email protected] (J.R.-E.) 2 Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México, Cuernavaca, Morelos 62210, Mexico; E-Mails: [email protected] (M.H.-O.); [email protected] (S.E.-G.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +52-477-7143-812; Fax: +52-477-7167-623. Received: 4 April 2014; in revised form: 14 May 2014 / Accepted: 19 May 2014 / Published: 30 May 2014 Abstract: Type 2 diabetes mellitus is characterized by hyperglycemia and insulin-resistance. Diabetes results from pancreatic inability to secrete the insulin needed to overcome this resistance. We analyzed the protein profile from the pancreas of ten-week old diabetic db/db and wild type mice through proteomics. Pancreatic proteins were separated in two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and significant changes in db/db mice respect to wild type mice were observed in 27 proteins. -
Carboxypeptidase N (Kininase I) (Kdnins/Anaphylatoxins/Kallikrein/Proteases/Carboxypeptidase B) YEHUDA LEVIN*T, RANDAL A
Proc. NatL Acad. Sci. USA Vol. 79, pp. 4618-4622, August 1982 Biochemistry Isolation and characterization of the subunits of human plasma carboxypeptidase N (kininase I) (kdnins/anaphylatoxins/kallikrein/proteases/carboxypeptidase B) YEHUDA LEVIN*t, RANDAL A. SKIDGEL*, AND ERVIN G. ERDOS*t§ Departments of *Pharmacology and UInternal Medicine, University of Texas Health Science Center, 5323 Harry Hines Boulevard, Dallas, Texas 75235 Communicated by P. Kusch, May 13, 1982 ABSTRACT Carboxypeptidase N (kininase I, arginine car- MATERIALS AND METHODS boxypeptidase; EC 3.4.17.3) cleaves COOH-terminal basic amino the Parkland Me- acids of kinins, anaphylatoxins, and other peptides. The tetra- Outdated human plasma was obtained from meric enzyme of Mr 280,000 was purified from.human plasma by morial Hospital blood bank (Dallas, TX). Hippurylargininic acid ion-exchange and arginine-Sepharose affinity chromatography. (Vega Biochemicals, Tucson, AZ), bradykinin (Bachem Fine Treatment with 3 M guanidine dissociated the enzyme into sub- Chemicals, Torrance, CA), guanidine'HCI (Chemalog, South units of 83,000 and 48,000 molecular weight, which were sepa- Plainfield, NJ), trypsin (Worthington, Freehold, NJ), and hu- rated and purified by gel filtration or affinity chromatography. man plasmin [Committee on Thrombolytic Agents (CTA) Stan- When tested with hippurylarginine, hippurylargininic acid, ben- dard, 10 units/ml, the American National'Red Cross] were used zoylalanyllysine, or bradyldkini the Mr 48,000 subunit was as ac- as received. Human urinary kallikrein was donated by H. Fritz tive as the intact enzyme-and was easily distinguished from human (Munich, Federal Republic of Germany) and human plasma pancreatic carboxypeptidase B (EC 3.4.17.2). -
ONLINE SUPPLEMENTARY TABLE Table 2. Differentially Expressed
ONLINE SUPPLEMENTARY TABLE Table 2. Differentially Expressed Probe Sets in Livers of GK Rats. A. Immune/Inflammatory (67 probe sets, 63 genes) Age Strain Probe ID Gene Name Symbol Accession Gene Function 5 WKY 1398390_at small inducible cytokine B13 precursor Cxcl13 AA892854 chemokine activity; lymph node development 5 WKY 1389581_at interleukin 33 Il33 BF390510 cytokine activity 5 WKY *1373970_at interleukin 33 Il33 AI716248 cytokine activity 5 WKY 1369171_at macrophage stimulating 1 (hepatocyte growth factor-like) Mst1; E2F2 NM_024352 serine-throenine kinase; tumor suppression 5 WKY 1388071_x_at major histocompatability antigen Mhc M24024 antigen processing and presentation 5 WKY 1385465_at sialic acid binding Ig-like lectin 5 Siglec5 BG379188 sialic acid-recognizing receptor 5 WKY 1393108_at major histocompatability antigen Mhc BM387813 antigen processing and presentation 5 WKY 1388202_at major histocompatability antigen Mhc BI395698 antigen processing and presentation 5 WKY 1371171_at major histocompatability antigen Mhc M10094 antigen processing and presentation 5 WKY 1370382_at major histocompatability antigen Mhc BI279526 antigen processing and presentation 5 WKY 1371033_at major histocompatability antigen Mhc AI715202 antigen processing and presentation 5 WKY 1383991_at leucine rich repeat containing 8 family, member E Lrrc8e BE096426 proliferation and activation of lymphocytes and monocytes. 5 WKY 1383046_at complement component factor H Cfh; Fh AA957258 regulation of complement cascade 4 WKY 1369522_a_at CD244 natural killer -
Serine Proteases with Altered Sensitivity to Activity-Modulating
(19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants. -
High-Resolution Mass Spectrometry-Based Approaches for the Detection and Quantification of Peptidase Activity in Plasma
molecules Article High-Resolution Mass Spectrometry-Based Approaches for the Detection and Quantification of Peptidase Activity in Plasma Elisa Maffioli 1,2 , Zhenze Jiang 3, Simona Nonnis 1,2 , Armando Negri 1,2, Valentina Romeo 1, Christopher B. Lietz 3, Vivian Hook 3,4, Giuseppe Ristagno 5, Giuseppe Baselli 6, Erik B. Kistler 7,8 , Federico Aletti 9, Anthony J. O’Donoghue 3,* and Gabriella Tedeschi 1,2,* 1 Department of Veterinary Medicine, University of Milano, 20133 Milano, Italy; elisa.maffi[email protected] (E.M.); [email protected] (S.N.); [email protected] (A.N.); [email protected] (V.R.) 2 Centre for Nanostructured Materials and Interfaces (CIMAINA), University of Milano, 20133 Milano, Italy 3 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA; [email protected] (Z.J.); [email protected] (C.B.L.); [email protected] (V.H.) 4 Department of Neurosciences, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA 5 Department of Pathophysiology and Transplantation, University of Milan, 20133 Milan, Italy; [email protected] 6 Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, 20133 Milan, Italy; [email protected] 7 Department of Anesthesiology & Critical Care, University of California San Diego, La Jolla, CA 92093, USA; [email protected] 8 Department of Anesthesiology & Critical Care, VA San Diego HealthCare System, San Diego, CA 92161, USA 9 Department of Bioengineering, University of California San Diego, La Jolla, CA 92093, USA; [email protected] * Correspondence: [email protected] (A.J.O.); [email protected] (G.T.); Tel.: +1-8585345360 (A.J.O.); +39-02-50318127 (G.T.) Academic Editor: Paolo Iadarola Received: 28 July 2020; Accepted: 4 September 2020; Published: 6 September 2020 Abstract: Proteomic technologies have identified 234 peptidases in plasma but little quantitative information about the proteolytic activity has been uncovered. -
Structure and Function of a Serine Carboxypeptidase Adapted for Degradation of the Protein Synthesis Antibiotic Microcin C7
Structure and function of a serine carboxypeptidase adapted for degradation of the protein synthesis antibiotic microcin C7 Vinayak Agarwala,b, Anton Tikhonovc,d, Anastasia Metlitskayac, Konstantin Severinovc,d,e, and Satish K. Naira,b,f,1 aCenter for Biophysics and Computational Biology, bInstitute for Genomic Biology, and fDepartment of Biochemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, IL 61801; cInstitutes of Molecular Genetics and Gene Biology, Russian Academy of Sciences, Moscow 11934, Russia; eDepartment of Molecular Biology and Biochemistry, and dWaksman Institute, Rutgers, State University of New Jersey, Piscataway, NJ 08854 Edited by Perry Allen Frey, University of Wisconsin, Madison, WI, and approved January 20, 2012 (received for review August 30, 2011) Several classes of naturally occurring antimicrobials exert their activity is exerted after intracellular processing. Examples of antibiotic activity by specifically targeting aminoacyl-tRNA synthe- naturally occurring antibiotics that employ this Trojan horse strat- tases, validating these enzymes as drug targets. The aspartyl tRNA egy include the LeuRS inhibitor agrocin 84 (in which the toxic synthetase “Trojan horse” inhibitor microcin C7 (McC7) consists of a group is linked through a phosphoramidate bond to a D-glucofur- nonhydrolyzable aspartyl-adenylate conjugated to a hexapeptide anosyloxyphosphoryl moiety) (5), the SerRS inhibitor albomycin carrier that facilitates active import into bacterial cells through an (a toxic group covalently linked to a hydroxymate siderophore) oligopeptide transport system. Subsequent proteolytic processing (6), and the AspRS inhibitor microcin C7 (Fig. 1A, 1) (McC7; releases the toxic compound inside the cell. Producing strains consisting of a modified aspartyl-adenylate linked to a six-residue of McC7 must protect themselves against autotoxicity that may re- peptide carrier). -
Protein Digestibility of Cereal Products
foods Communication Protein Digestibility of Cereal Products Iris Joye Department of Food Science, University of Guelph, Guelph, ON N1G 2W1, Canada; [email protected]; Tel.: +1-519-824-4120 (ext. 52470) Received: 5 May 2019; Accepted: 3 June 2019; Published: 8 June 2019 Abstract: Protein digestibility is currently a hot research topic and is of big interest to the food industry. Different scoring methods have been developed to describe protein quality. Cereal protein scores are typically low due to a suboptimal amino acid profile and low protein digestibility. Protein digestibility is a result of both external and internal factors. Examples of external factors are physical inaccessibility due to entrapment in e.g., intact cell structures and the presence of antinutritional factors. The main internal factors are the amino acid sequence of the proteins and protein folding and crosslinking. Processing of food is generally designed to increase the overall digestibility through affecting these external and internal factors. However, with proteins, processing may eventually also lead to a decrease in digestibility. In this review, protein digestion and digestibility are discussed with emphasis on the proteins of (pseudo)cereals. Keywords: protein digestibility; cereals; pseudocereals; processing; antinutritional factors 1. Introduction Proteins are abundantly present in all living cells, and as such are a vital part of our diet. In order to be usable to the human body after ingestion, dietary proteins have to be hydrolysed into their basic building blocks, i.e., amino acids or small peptides. Hereto, the human gastrointestinal tract possesses an assortment of protein hydrolysing enzymes or peptidases. The physiological roles of proteins are very diverse and range from functioning as pure nitrogen storage molecules over delivering structure building capacity to catalysing a myriad of reactions as metabolically active enzymes or serving as transporter vehicles for poorly soluble or physiologically unstable components [1]. -
Two Distinct Gene Subfamilies Within the Family of Cysteine Protease Genes (Tetrahymena/Propeptide/Cathepsin) KATHLEEN M
Proc. Natl. Acad. Sci. USA Vol. 90, pp. 3063-3067, April 1993 Biochemistry Two distinct gene subfamilies within the family of cysteine protease genes (tetrahymena/propeptide/cathepsin) KATHLEEN M. KARRER*, STACIA L. PEIFFERt, AND MICHELE E. DITOMAS Department of Biology, Marquette University, Milwaukee, WI 53233 Communicated by David M. Prescott, January 7, 1993 ABSTRACT A cDNA clone for a physiologically regulated (4, 5). The clone was isolated from a cDNA library of RNA Tetrahymena cysteine protease gene was sequenced. The nu- from starved cells cloned into the Pst I site ofpUC9 (4). DNA cleotide sequence predicts that the clone encodes a 336-amino fragments were subcloned into pBluescript for sequencing. acid protein composed of a 19-residue N-terminal signal se- The sequence was scanned for open reading frames by using quence followed by a 107-residue propeptide and a 210-residue the DNA INSPECTOR IIE program (Textco), taking into con- mature protein. Comparison of the deduced amino acid se- sideration that in Tetrahymena, as in several ciliates, TAA quence of the protein with those of other cysteine proteases and TAG code for Gln (6-8). DNA sequences that code for revealed a highly conserved interspersed amino acid motif in homologous proteins were identified through a Pearson and the propeptide region of the protein, the ERFNIN motif. The Lipman (9) search ofthe EMBL/GenBank data base by using motifwas present in all ofthe cysteine proteases in the data base with the exception of the cathepsin B-like proteins, which have the TFASTA program. shorter propeptides. Differences in the propeptides and in conserved amino acids of the mature proteins suggest that the RESULTS ERFNIN proteases and the cathepsin B-like proteases consti- tute two distinct subfamilies within the cysteine proteases. -
Partial Characterisation of Dipeptidyl Peptidase 4 (DP 4
Partial Characterisation of Dipeptidyl Peptidase 4 (DP 4) for the Treatment of Type 2 Diabetes and its Identification as a novel Pharmaceutical Target for Stress-related Indications Beiträge zur Charakterisierung der Dipeptidylpeptidase 4 (DP 4) für die Behandlung von Typ-2-Diabetes und deren Identifizierung als ein neuartiges pharmazeutisches Ziel für stressvermittelte Indikationen Der Naturwissenschaftlichen Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg zur Erlangung des Doktorgrades Dr. rer. nat. vorgelegt von M. Sc. (Biochemie) Leona Wagner aus Rheinfelden (Baden) Als Dissertation genehmigt von der Naturwissenschaftlichen Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg Tag der mündlichen Prüfung: 23.10.2012 Vorsitzender der Promotionskommission: Prof. Dr. Rainer Fink Erstberichterstatter: Prof. Dr. med. Stephan von Hörsten Zweitberichterstatter: Prof. Dr. Johann Helmut Brandstätter Publications, Presentations and Posters Part of the present study have been published or submitted in the following journals or presented on the following conferences: Publications: 1. Hinke, S.A., McIntosh, C.H., Hoffmann, T., Kuhn-Wache, K., Wagner, L., Bar, J., Manhart, S., Wermann, M., Pederson, R.A., and Demuth, H.U. (2002) On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors. Diabetes Care 25, 1490- 1491. 2. Bär, J., Weber, A., Hoffmann, T., Stork, J., Wermann, M., Wagner, L., Aust, S., Gerhartz, B., and Demuth, H.U. (2003) Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme. Biol. Chem. 384, 1553-1563. 3. Engel, M., Hoffmann, T., Wagner, L., Wermann, M., Heiser, U., Kiefersauer, R., Huber, R., Bode, W., Demuth, H.U., and Brandstetter, H.